Table 1.

Baseline Characteristics

Characteristic	Overall n = 30	Nintedanib n = 18	Placebo n = 12
Age in years	72 (47–86)	72 (58–80)	70 (47–86)
Sex
Female	22 (73%)	13 (72%)	9 (75%)
Male	8 (27%)	5 (28%)	3 (25%)
Race
Asian	3 (10%)	1 (6%)	2 (17%)
Black or African American	1 (3%)	0	1 (8%)
Not reported	1 (3%)	0	1 (8%)
White	25 (83%)	17 (94%)	8 (67%)
Smoking Status
Former	24 (83%)	15 (83%)	9 (82%)
Never	5 (17%)	3 (17%)	2 (18%)
KPS	80 (70–100)	80 (70–90)	80 (70–100)
Radiation Dose
48–50 Gy / 4–5 fxns	8 (27%)	4 (22%)	4 (33%)
45–60 Gy / 10–20 fxns	3 (10%)	2 (11%)	1 (8%)
45–66 Gy / 25–35 fxns	19 (63%)	12 (67%)	7 (58%)
Pneumonitis Grade
Grade 2	24 (80%)	14 (78%)	10 (83%)
Grade 3	6 (20%)	4 (22%)	2 (17%)
Prior Steroids	24 (80%)	13 (72%)	11 (92%)
Cancer Type
NSCLC	22 (73%)	14 (78%)	8 (67%)
Stage I	4 (13%)	2 (11%)	2 (17%)
Stage II	2 (7%)	0	2 (17%)
Stage III	12 (40%)	8 (44%)	4 (33%)
Stage IV	3 (10%)	3 (17%)	0
Mesothelioma	2 (7%)	2 (11%)	0
Thymoma	2 (7%)	1 (6%)	1 (8%)
SCLC	3 (10%)	1 (6%)	2 (17%)
Other	1 (3%)	0	1 (8%)

Baseline characteristics of enrolled participants. Reported as median (range) for age and KPS, otherwise number (percent). Prior steroids refers to corticosteroid use <=4 weeks prior to enrollment. NSCLC – Non-small cell lung cancer, SCLC-small cell lung cancer. fxns- fractions